Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.33 |
| ▸ | TPI1 | P60174 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429502 | 0.92 | SAT1 (0.50) | SAT1LPAR3LPAR2LPAR1S1PR2 | |
| SCHEMBL3429864 | 0.89 | SAT1 (0.38) | SAT1LPAR3LPAR2LPAR1ENPP2 | |
| SCHEMBL3429682 | 0.87 | LPAR3 (0.39) | SAT1LPAR3LPAR2LPAR1ENPP2 | |
| SCHEMBL17859165 | 0.87 | LPAR3 (0.44) | SAT1LPAR3LPAR2LPAR1ENPP2 | |
| SCHEMBL3429975 | 0.83 | SAT1 (0.42) | SAT1LPAR3LPAR2LPAR1ENPP2 | |
| SCHEMBL9172734 | 0.82 | DRD3 (0.52) | SAT1LPAR3LPAR2LPAR1 | |
| SCHEMBL13400489 | 0.82 | LPAR3 (0.59) | SAT1LPAR3LPAR2LPAR1ENPP2 | |
| SCHEMBL14782501 | 0.81 | ANPEP (0.44) | SAT1LPAR3LPAR2LPAR1ENPP2 | |
| SCHEMBL5978775 | 0.80 | LPAR3 (0.62) | SAT1LPAR3LPAR2LPAR1ENPP2 | |
| SCHEMBL31086327 | 0.79 | CA12 (0.46) | SAT1LPAR3LPAR2LPAR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | SAT1 2675/4885LPAR3 3825/4885LPAR2 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.